As the new cases and related deaths fall in sub-Saharan Africa, the virus is rearing its head elsewhere. What's the cause?

Merck's experimental two-drug combination met the main goal of significantly suppressing replication of the HIV-1 virus in ...

U.S. drugmaker Merck said on Thursday its experimental combination treatment for some adults with HIV-1 infection met the ...

As we mark the holidays, here are a few of the many heroes who are working to build a stronger global health future by ...

To reflect on the current use and future potential of HIV financial data, UNAIDS and the Global Fund to Fight AIDS, TB and ...

There is hope for a new 5 by 3 global target of getting 5 million people on long-acting PrEP to prevent HIV by 2030.

Merck (MRK) stock in focus as company reports mixed results in Phase 3 trials for HIV therapy islatravir in combination with ...

Gilead Sciences will no longer provide four HIV medicines for free as part of a patient assistance program starting at the ...

What does the HIV response look like beyond the 2030 targets to end AIDS? For the past year, UNAIDS has been working with ...

Merck shares Phase 3 trial results for its HIV-1 regimen, doravirine/islatravir, showing safety and comparable efficacy to ...

HIV is spreading faster in the South than in the rest of the country. Founder of Seeds of Healing, LeShonda Wallace, said ...